Displaying 198 (all) recruiting clinical trials.
-
A single arm open-label multicenter phase II study of 177Lu-DOTATATE radionuclide in adults with progressive or high-risk meningioma
The purpose of this research study is to test whether Lutathera® (177Lu-DOTATATE) is effective (how well something works) at stopping the growth of meningiomas. This ... -
An Open-Label Multicenter Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
The purpose of this study is to see how well RP1 is tolerated by the body and to determine the safest dose of RP1 for ... -
A Phase 2 Open-label Multicenter Study of an Immunotherapeutic Treatment DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab in Subjects with Selected Advanced and Recurrent Solid Tumours.
In this study, we are trying to determine the safety and ability of an investigational product, called DPX Survivac, to help the immune system fight ... -
A Randomized Non-Comparative Phase II Study of Nivolumab or Nivolumab/BMS-986205 alone or combined with Intravesical BCG in Patients with BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer
If you have been diagnosed with BCG unresponsive, high-risk, non-muscle invasive bladder cancer, you may qualify for this study. The main purpose of the study ... -
A phase III multicenter randomized open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive HER2-negative early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE).
The purpose of the trial is to evaluate the efficacy and the safety of ribociclib when given in combination with endocrine (hormonal) therapy, compared to ... -
A Phase II Study of High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
The purpose of this study is to determine the rate of graft-versus-host disease (GvHD) for patients receiving bortezomib, known commercially as Velcade®, and cyclophosphamide, known ... -
EA9161: A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
This study is being done to answer the following question: What are the good and bad effects of a time limited administration of a targeted ... -
Open-label Multicenter Phase 2 Study Evaluating the Efficacy & Safety of Daratumumab in Pediatric & Young Adult Subjects =1 & =30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
If you have been diagnosed with with Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, you may be qualified for this ... -
A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (mRNA-4157-P201)
The purpose of this research study is to test whether the combination of the study drugs pembrolizumab and mRNA-4157 works better than just pembrolizumab to ... -
A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
The purpose of this study is to: • Test the safety of the study drug (olaparib), see how well the drug works, and see how your ...